EIC Transition 2022


Who can apply for the EIC Transition 2022?

Single applicants or small consortia of minimum 2 to maximum 5 partners. 

Proposals must build on results from EIC Pathfinder, FET projects or ERC Proof of Concept. 

  • A single entity can apply.
  • A small consortium of two independent entities from two different Member States (MS) or Associated Countries (AC) can apply.
  • If consortium >2 and ⩽5, then standard rules apply: i.e. from at least 3 different MS or AC and at least 1 established in a MS.

When to apply for the EIC Transition in 2022?

The EIC Transition is a 2-step process.

Step 1: Proposal of maximum 20 pages. Step 2: Face-to-face interview.

The EIC Transition has 2 cut-off dates in 2022. The first is on 04/05. The second is on 28/09.

Step 1

20 page Proposal

Step 2

Face-to-face Interview

Funding Options

Grants of up to €2.5m.

  • Project budget: €500k to €2.5m.
  • Project duration: 1 to 3 years.
  • Funding rate: 100%.
  • €50k Booster grant available.

The projects funded through EIC Transition are eligible:

  • To receive additional EIC Booster grants.
  • To submit an EIC Accelerator proposal via the Fast Track scheme.

Open Call


04/05/2022 - 28/09/2022.

Grants of max. €2.5m.

Funding Rate

Challenge Call


04/05/2022 - 28/09/2022.

Grants of max. €2.5m.

Funding Rate

Challenge Topics

General objectives:

To radically improve or solve one or several of the following key issues of ICT solutions: energy efficiency, use of non-critical and non-toxic raw materials, ensuring circular approaches and/or a high degree of recyclability, while maintaining or even improving on performance and miniaturisation.

The goal is tackling as many of them as possible, ideally all. A business model, its initial validation and a business plan are also expected outcomes of the project.

General objectives:

Energy recovery, conversion and storage (including Renewable fuels) to reach 2030 emissions reduction targets and Fit for 55 goals. 

General objectives:

Novel delivery strategies providing more effective and safer delivery of the mRNA-based therapeutic into most type of cells, are required for mRNA based clinical candidates.  

Other types of RNAs (e.g. tRNA, siRNAs, miRNAs), with other mechanisms of action can be used to target nearly all disease-related genes of interest. In the case of these RNAs too, challenges exist like the intracellular delivery of mRNA limiting their clinical utility and the possible induction of off-target effects, both of which represent major hurdles.

Contact us

Contact us to learn more about the EIC Transition.